

Abstract

A crystalline salicylate monohydrate salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. A method to make crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is further disclosed. In addition, methods of use for crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine are disclosed.